Relationship between dose, exposure, and antitumoral activity of sorafenib in melanoma

Authors :: Manuelle Viguier
Isabelle Gorin
C. Lebbé
D. Kerob
B. Billemont
P. Herait
Nicolas Pécuchet
Benoit Blanchet
M.-F. Avril
François Goldwasser
Source :: Journal of Clinical Oncology. 28:8582-8582
Publication Year :: 2010
Publisher :: American Society of Clinical Oncology (ASCO), 2010.
Abstract: 8582 Background: Interpatient variability in sorafenib (SOR) bioavailability and too-early treatment discontinuation might account for poor efficacy results of SOR in melanoma. A cohort of poor pro...

Subjects :: Sorafenib
Oncology
Cancer Research
medicine.medical_specialty
business.industry
Melanoma
medicine.disease
Bioavailability
Discontinuation
Internal medicine
Cohort
medicine
business
neoplasms
medicine.drug

Full Text Access

Tools